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A B S T R A C T
The novel coronavirus SARS-CoV-2 can cause a severe and even fatal respiratory illness named COVID-19.
Apart from respiratory failure, COVID-19 may be associated with various autoimmune complications. We
present a case of a critically ill patient with COVID-19 who developed severe immune thrombocytopenia
that was successfully treated with a concomitant use of corticosteroids and intravenous immunoglo-
bulins.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Coronavirus disease (COVID-19) follows a mild course in about
80 % of cases, but some patients develop severe pneumonia and
other non-pulmonary life-threatening complications (Wu and
McGoogan 2020). Among the latter, thrombotic events, hyper-
inflammatory syndrome and autoimmune diseases have been
described as important features of severe disease (Galeotti and
Bayry 2020; Levi et al. 2020). Immune thrombocytopenia (ITP) is
an autoantibody and T-cell-mediated autoimmune disorder
characterized by isolated thrombocytopenia, which can be
triggered by infection (Cines et al. 2009). First line treatment of
severe ITP includes platelet transfusions, corticosteroids and
intravenous immunoglobulins (IVIG) (Provan et al. 2019). Very
few cases of COVID-19- associated ITP have been reported so far,
especially in critically ill patients. Moreover, treatment of severe
COVID-19-associated ITP in critically ill patients may be particu-
larly challenging. Besides known side effects, corticosteroids may
have detrimental effects on immune function and viral clearance
and effects of both corticosteroids and IVIG on COVID-19 outcome
are currently unknown (Russell et al. 2020). On the other hand,
concomitant treatment with corticosteroids and IVIG may be
associated with rapid treatment response in ITP (Neunert et al.* Corresponding author.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).2011). We present a case of a critically ill COVID-19 patient with
severe ITP, which was successfully treated with a concomitant use
of corticosteroids and IVIG.
Case report
A 48-year-old man with type 2 diabetes, obesity (BMI 43.4 kg/
m2) and obstructive sleep apnea presented to the emergency
department on 29thMarch 2020 with a 3-day history of progressive
dyspnea, cough, fever with the highest temperature of 38.5 C,
headache and muscle soreness. His only regular medication was
metformin. On examination, he had a respiratory rate of 42 breaths
per minute and oxygen saturation of 60% while receiving high flow
oxygen (15 L/min) via a non-rebreather mask. Other vitals revealed
a body temperature of 37.5 C, pulse 125 beats per minute and
blood pressure 163/60 mmHg. The patient was promptly
transferred to the intensive care unit (ICU), sedated, intubated,
and mechanically ventilated. A chest X-ray showed diffuse bilateral
consolidations and a reverse transcription polymerase chain
reaction (RT-PCR) test of a nasopharyngeal swab was positive
for SARS-CoV-2. Co-infection with other respiratory viruses,
including influenza, was excluded by multiplex nasopharyngeal
RT-PCR test. Blood tests on admission showed a white blood cell
count of 16,700/mm3, C-reactive protein of 293 mg/L, procalcitonin
of 2.31 mg/L, a creatinine of 188 mmol/L, a fibrinogen of 9.4 g/L and
a D-dimer of 1,675 mg/L. The platelet count and hemoglobin level
were normal (347,000/mm3 and 13,7 g/dL, respectively). Inciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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therapy with lopinavir/ritonavir 400 mg/100 mg BID and
hydroxychloroquine sulphate 400 mg BID (on the first day,
followed by 200 mg BID) via nasogastric tube was initiated. The
patient also received piperacillin/tazobactam 4 g/0.5 g QID
intravenously, sedation with fentanyl and midazolam, low-dose
noradrenalin, pantoprazole and thromboprophylaxis with nadro-
parin 5,600 IU daily. Hepatitis B (HBV), hepatitis C (HCV) and
human immunodeficiency virus (HIV) serologic tests were
negative.
On the 9th day after admission, macroscopic hematuria
developed after a non-traumatic re-insertion of a urinary
catheter. Concurrently, minor bleeding from oral mucosa and
blood clots in gastric residual volume were observed. Upper
gastrointestinal tract endoscopy showed non-bleeding ulcers at
the tip of the nasogastric tube, for which no intervention was
needed. Complete blood count revealed an isolated thrombocy-
topenia with a platelet count of 96,000/mm3, with a further
decline to 2,000/mm3 on the 12th day. At that time petechial
bleeding appeared on the torso. Due to severe thrombocytopenia,
low molecular weight heparin (LMWH) and antiviral therapies
were discontinued. Other blood tests showed normal coagulation
times and moderately elevated fibrinogen, D-dimer, and ferritin
levels (4.8 g/L, 2,244 mg/L and 766 mg/L, respectively). The
percentage of schistocytes in peripheral blood, haptoglobin and
bilirubin were normal. Direct Coombs test was positive for IgG,
indirect Coombs test was negative. Heparin-induced thrombo-
cytopenia (HIT) antibodies were negative. Quantitative cyto-
megalovirus PCR test was negative and quantitative Epstein-Barr
virus PCR test from plasma detected less than 2.88 log10 copies/
ml. Renal and liver function were improving. Due to the bleeding,
the patient received a transfusion of one unit (325 ml) of pooled
platelet concentrate with a one-hour post transfusion platelet
increment of 5,000/mm3 (from 4,000/mm3 to 9,000/mm3). Based
on these findings, a diagnosis of COVID-19-associated ITP was
suspected. The patient was started on IVIG for a total of 1 g per
kilogram of adjusted body weight (100 g), divided into two daily
doses (50 g/day) concomitantly with intravenous dexametha-
sone 40 mg daily. The platelet count rose to 185,000/mm3 on the
third day of treatment; therefore, corticosteroids were discon-
tinued after three daily doses. According to an inpatient
anticoagulation management service consultation, thrombopro-
phylaxis was restarted with a continuous infusion of unfractio-
nated heparin due to a higher risk of bleeding and moderate renal
failure. After renal function recovery, the therapy was changed
to higher dose prophylactic LMWH (dalteparin 7,500 IU q12 h)
and no bleeding or other adverse events were noted for the rest
of the treatment. At the end of the corticosteroid therapy,
improvement in oxygenation was noticed and a consecutive
chest X-ray showed regression of pulmonary consolidations. The
patient was successfully weaned from ventilator support and
extubated after 32 days of mechanical ventilation. No neurologic
complications were noted. The patient was transferred to
another hospital for further rehabilitation and was discharged
on 22th May 2020. The platelet count remained normal during
the rest of the hospitalization and on follow-up laboratory tests
in the next two months.
Discussion
Persistent thrombocytopenia in critically ill patients is
associated with increased mortality, so identification of the
underlying cause and early targeted treatment is crucial (Brogly
et al. 2007). In our patient, the diagnosis of COVID-19-associated
ITP is supported by an isolated thrombocytopenia, the chrono-
logical sequence of events, a low post-transfusion plateletincrement, the exclusion of other causes and a good response
to first line treatment. The SARS-CoV-2 has many immunogenic
peptides with homology to human proteins that have an
important role in the adaptive immune system (Lyons-Weiler
2020). That could explain the association between severe disease
presentations of COVID-19 and the reported autoimmune
complications (Lazarian et al. 2020).
At the time of writing of this report, only two cases of COVID-
19-associated ITP have been described in critically ill patients
(Bomhof et al. 2020; Lévesque et al. 2020). One patient died due to
intracerebral bleeding before corticosteroid and IVIG was
initiated. In another case, the application of IVIG followed by
high dose dexamethasone did not result in improvement of
platelet count; therefore, second-line therapy and extensive
transfusion support was needed to achieve an adequate platelet
count and stop the bleeding. In our case, treatment with high dose
dexamethasone and IVIG was started concomitantly as soon as
other probable causes of thrombocytopenia were excluded. This
led to a rapid increase in platelets and prevented further bleeding.
Importantly, extensive transfusion of blood components was
avoided as well as transfusion related complications. Further-
more, although the follow-up period is short, there is no relapse
of thrombocytopenia.
According to recently published guidelines from a working
group of German, Austrian and Swiss experts, for emergency
treatment of ITP complicated by severe bleeding, IVIG should be
administered in addition to corticosteroids to increase platelet
count rapidly (Matzdorff et al. 2018). As randomized trials on this
topic are lacking, this recommendation is supported by small
observational studies; therefore, we believe that our case adds to
the body of evidence that this approach may be beneficial in
critically ill patients.
Finally, of interest is the fact that we observed an improvement
in oxygenation following dexamethasone and IVIG treatment. This
effect should be interpreted with caution, as the improvement also
could be attributed to supportive treatment or to a natural course
of the disease. It should be stressed that dexamethasone was
initiated late in the COVID-19 course (15th day of illness), by which
time the inflammatory phase was in resolution, according to
decrement of inflammatory markers. In COVID-19, the use of
corticosteroids is controversial until more evidence is available
(Russell et al. 2020). However, recently published preliminary
results of the RECOVERY trial point to a beneficial effect of
dexamethasone regarding 28-day mortality, especially in patients
who require oxygen supplementation and mechanical ventilation
(Horby et al. 2020). Regarding IVIG, there have been limited reports
of its use in COVID-19 with inconsistent results. (Xie et al. 2020;
Zhang et al. 2020). On the basis of our experience with one patient,
we are not able to provide sufficient evidence that this therapy was
of benefit regarding the pneumonia.
Conclusion
ITP is a seemingly rare but important complication that can lead
to disability and higher mortality in COVID-19 patients. Early
recognition, diagnosis and treatment are essential to prevent
severe consequences. In our case, concomitant treatment with
corticosteroids and IVIG resulted in rapid increase in the
thrombocytes level, cessation of bleeding and improved oxygen-
ation without therapy related side effects.
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